Geode Capital Management’s Fortress Biotech FBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$810K Buy
290,255
+27,763
+11% +$94.4K ﹤0.01% 3429
2025
Q4
$961K Buy
262,492
+18,071
+7% +$51.5K ﹤0.01% 3393
2025
Q3
$904K Buy
244,421
+9,631
+4% +$24.4K ﹤0.01% 3413
2025
Q2
$437K Sell
234,790
-2,744
-1% -$4.75K ﹤0.01% 3596
2025
Q1
$371K Buy
237,534
+32,997
+16% +$58.2K ﹤0.01% 3654
2024
Q4
$414K Buy
204,537
+35,930
+21% +$65.1K ﹤0.01% 3669
2024
Q3
$244K Buy
168,607
+37,736
+29% +$71.9K ﹤0.01% 3844
2024
Q2
$224K Buy
130,871
+17,554
+15% +$31.8K ﹤0.01% 3870
2024
Q1
$227K Buy
113,317
+56,618
+100% +$113K ﹤0.01% 3899
2023
Q4
$171K Sell
56,699
-3,328
-6% -$8.8K ﹤0.01% 3997
2023
Q3
$261K Buy
60,027
+2,735
+5% +$18.8K ﹤0.01% 3873
2023
Q2
$473K Buy
57,292
+10,740
+23% +$106K ﹤0.01% 3664
2023
Q1
$573K Buy
46,552
+1,337
+3% +$15.9K ﹤0.01% 3588
2022
Q4
$444K Sell
45,215
-102
-0.2% -$1.13K ﹤0.01% 3713
2022
Q3
$584K Buy
45,317
+149
+0.3% +$2.23K ﹤0.01% 3640
2022
Q2
$569K Sell
45,168
-39,640
-47% -$587K ﹤0.01% 3696
2022
Q1
$1.73M Sell
84,808
-5,032
-6% -$138K ﹤0.01% 3328
2021
Q4
$3.37M Sell
89,840
-905
-1% -$40.4K ﹤0.01% 3109
2021
Q3
$4.38M Buy
90,745
+3,159
+4% +$154K ﹤0.01% 2985
2021
Q2
$4.69M Buy
87,586
+9,555
+12% +$576K ﹤0.01% 2953
2021
Q1
$4.13M Buy
78,031
+15,850
+25% +$894K ﹤0.01% 2883
2020
Q4
$2.96M Buy
62,181
+3,054
+5% +$132K ﹤0.01% 2873
2020
Q3
$3.58M Buy
59,127
+8,862
+18% +$451K ﹤0.01% 2578
2020
Q2
$2.02M Buy
50,265
+27,187
+118% +$1.01M ﹤0.01% 2832
2020
Q1
$654K Sell
23,078
-222
-1% -$7.37K ﹤0.01% 3185
2019
Q4
$898K Sell
23,300
-198
-0.8% -$5.08K ﹤0.01% 3314
2019
Q3
$496K Sell
23,498
-245
-1% -$5.76K ﹤0.01% 3471
2019
Q2
$534K Sell
23,743
-9,433
-28% -$243K ﹤0.01% 3446
2019
Q1
$885K Buy
33,176
+7,845
+31% +$206K ﹤0.01% 3207
2018
Q4
$326K Buy
25,331
+2,882
+13% +$48.1K ﹤0.01% 3524
2018
Q3
$538K Buy
22,449
+896
+4% +$28.7K ﹤0.01% 3436
2018
Q2
$963K Buy
21,553
+1,406
+7% +$79.2K ﹤0.01% 3202
2018
Q1
$1.38M Buy
20,147
+299
+2% +$18.9K ﹤0.01% 2966
2017
Q4
$1.19M Buy
19,848
+204
+1% +$12K ﹤0.01% 3025
2017
Q3
$1.3M Buy
19,644
+46
+0.2% +$3.1K ﹤0.01% 2998
2017
Q2
$1.4M Buy
19,598
+360
+2% +$21.3K ﹤0.01% 2934
2017
Q1
$1.07M Buy
19,238
+597
+3% +$26.7K ﹤0.01% 2986
2016
Q4
$754K Buy
18,641
+521
+3% +$19.5K ﹤0.01% 3118
2016
Q3
$807K Buy
18,120
+549
+3% +$23.3K ﹤0.01% 3060
2016
Q2
$708K Buy
17,571
+2,219
+14% +$103K ﹤0.01% 3062
2016
Q1
$713 Sell
15,352
-14
-0.1% -$591 ﹤0.01% 3053
2015
Q4
$643K Buy
15,366
+658
+4% +$27.6K ﹤0.01% 3147
2015
Q3
$573K Buy
+14,708
New +$687K ﹤0.01% 3165
2015
Q2
Sell
-14,720
Closed -$850K 3973
2015
Q1
$850K Buy
14,720
+2,143
+17% +$89.3K ﹤0.01% 2949
2014
Q4
$460K Buy
12,577
+19
+0.2% +$560 ﹤0.01% 3233
2014
Q3
$395K Buy
12,558
+4,640
+59% +$123K ﹤0.01% 3268
2014
Q2
$204K Sell
7,918
-1,249
-14% -$32.9K ﹤0.01% 3517
2014
Q1
$272K Buy
9,167
+2,634
+40% +$103K ﹤0.01% 3395
2013
Q4
$257K Buy
6,533
+13
+0.2% +$502 ﹤0.01% 3342
2013
Q3
$687K Buy
6,520
+352
+6% +$43.2K ﹤0.01% 2791
2013
Q2
$796K Buy
+6,168
New +$909K ﹤0.01% 2603

Other funds holding FBIO

Geode Capital Management's FBIO Position: Q1 2026 in Review

Geode Capital Management increased its Fortress Biotech (FBIO) stake by 11% in Q1 2026, buying an estimated $94.4K and bringing the position to 290,255 shares worth $810K. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

Geode Capital Management first reported a position in FBIO in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.69M in Q2 2021. 51 funds tracked by Wall St. Rank hold FBIO as of Q1 2026.

  • Geode Capital Management held 290,255 shares of Fortress Biotech worth $810K as of Q1 2026.
  • Geode Capital Management bought 27,763 Fortress Biotech shares in Q1 2026, an estimated $94.4K.
  • Fortress Biotech made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3429 holding.
  • Geode Capital Management first reported a position in Fortress Biotech in Q2 2013 and has held it in 51 quarters since.
  • Geode Capital Management's Fortress Biotech position peaked at $4.69M in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.